Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-847-9
CAS number: 127-52-6
Beagle dogs were dosed orally or intravenously, or
through a combination of the two, with doses ranging from approximately
12.8 to 640mg/kg per day for up to six months. In the study, 50% of the
animals were sacrificed at 17 weeks. At that time, persistent mild or
moderate anemia was observed. A reduction in Elastase Inhibitory
Concentration (EIC) was found in the serum from the dosed animals.
Furthermore, a reduction in EIC was found in the pulmonary lavage fluid.
However the levels of immunologically determined protease inhibitor did
not change with treatment, therefore, the enzyme must have been
inactivated by chloramine T. The reaction was specific for the protease
inhibitor, as the ability to inhibit trypsin was less affected.
Emphysema-like alterations in lung morphology were found in both
studies. The data suggest that this model parallels the emphysema
associated with the genetic alpha-l-proteinase inhibitor deficiency in
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again